Fri, 13 November 2015
Oil's low prices have stuck around much longer than so many originally thought. Now, more than a year later, we're starting to see companies buckle under the pressure. Our energy team looks at the implications and the lesson to learn from these companies' demise. |
Wed, 11 November 2015
Exelixis has a newly approved melanoma drug hitting the market soon and Colorado voters will weigh in on universal healthcare in 2016. |
Wed, 11 November 2015
Traditional apparel retailers like Macy’s and Nordstrom have limped through 2015. What is driving weakness in the sector, and what should investors watch in the latest quarter? |
Tue, 10 November 2015
Tune in for discussions on the NYCB-Astoria Financial merger, New York Mellon Bank, and whether or not CEOs should live near HQ. |
Sat, 7 November 2015
On this episode we talk earnings numbers, some cool stats from the conference call and check in on Facebook’s other big internet properties. |
Sat, 7 November 2015
Energy results are as diverse as the industry itself, and Motley Fool’s Tyler Crowe, Taylor Muckerman and Sean O’Reilly weigh in. |
Wed, 4 November 2015
Motley Fools dig into recent announcements that could impact the marijuana and hepatitis C markets next year. |
Sat, 31 October 2015
On this episode we dig into Apple’s record-setting quarter, explain why the market shouldn’t have been surprised, and figure out what segments fueled the company’s great top and bottom line growth. |
Fri, 30 October 2015
Oil sands are becoming more common in the energy sector, and with the amount of work it takes to clean these sands, it's no wonder the cost is so high. Shell not only dropped out of the Arctic after building up all the hype, but now they're letting go of oil sands projects, citing the company's business structure as the problem. All the while, a "cash crunch" is enveloping the Fab Four in the oil and gas sector, but although these numbers are huge to a layperson, their cash reserves seem to be singing a different tune. |
Wed, 28 October 2015
This week we're discussing Walgreens acquiring Rite Aid. Did this retail pharmacy giant play its cards right? Does an overlapping footprint mean the two retail pharmacies will step on each other’s toes? Tune in to find some answers. |